Serac Healthcare is focused on developing maraciclatide to help rheumatologists deliver personalised medicine to patients suffering with the devastating and debilitating disease; rheumatoid arthritis (RA).
Timely, aggressive therapy offers the best chance of achieving good long-term outcomes but many of the available biological therapies are expensive and immunosuppressant and it remains a challenge to identify patients who would most benefit from such treatment; full clinical assessments require significant hands-on time with a rheumatologist and symptoms do not always correlate with the underlying disease process.
Preliminary clinical data indicate that the molecular imaging agent maraciclatide, which has recently been acquired from GE, may allow rheumatologists to visualise active disease in the joints helping them to deliver the right treatment to the right patient at the right time (personalised medicine) leading to improved outcomes and quality of life.
The capability for the rapid, objective assessment of disease activity at the whole-body level, as we believe may be possible with maraciclatide imaging, addresses an important unmet medical need in the management of patients living with RA.
We also plan to evaluate other indications in which the αvβ3 integrin targeted by maraciclatide is over-expressed (e.g. Psoriatic Arthritis [PS], Enthesitis, Ankylosing Spondylitis [AS], tumours, inflammatory cardiovascular conditions and cardiac remodelling).
Download PDF of press release